Non-compliance with colonoscopy after a positive faecal immunochemical test doubles the risk of dying from colorectal cancer.
Fiche du document
- doi: 10.1136/gutjnl-2020-322192
- issn: 0017-5749
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1136/gutjnl-2020-322192
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33789965
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1468-3288
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_90AB05A8AD2E7
info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/
Sujets proches
ColoscopyCiter ce document
M. Zorzi et al., « Non-compliance with colonoscopy after a positive faecal immunochemical test doubles the risk of dying from colorectal cancer. », Serveur académique Lausannois, ID : 10.1136/gutjnl-2020-322192
Métriques
Partage / Export
Résumé
The risk of colorectal cancer (CRC) among subjects with a positive faecal immunochemical test (FIT) who do not undergo a colonoscopy is unknown. We estimated whether non-compliance with colonoscopy after a positive FIT is associated with increased CRC incidence and mortality. The FIT-based CRC screening programme in the Veneto region (Italy) invited persons aged 50 to 69 years with a positive FIT (>20 µg Hb/g faeces) for diagnostic colonoscopy at an endoscopic referral centre. In this retrospective cohort study, we compared the 10-year cumulative CRC incidence and mortality among FIT positives who completed a diagnostic colonoscopy within the programme (compliers) and those who did not (non-compliers), using the Kaplan-Meier estimator and Cox-Aalen models. Some 88 013 patients who were FIT positive complied with colonoscopy (males: 56.1%; aged 50-59 years: 49.1%) while 23 410 did not (males: 54.6%; aged 50-59 years: 44.9%).The 10-year cumulative incidence of CRC was 44.7 per 1000 (95% CI, 43.1 to 46.3) among colonoscopy compliers and 54.3 per 1000 (95% CI, 49.9 to 58.7) in non-compliers, while the cumulative mortality for CRC was 6.8 per 1000 (95% CI, 5.9 to 7.6) and 16.0 per 1000 (95% CI, 13.1 to 18.9), respectively. The risk of dying of CRC among non-compliers was 103% higher than among compliers (adjusted HR, 2.03; 95% CI, 1.68 to 2.44). The excess risk of CRC death among those not completing colonoscopy after a positive faecal occult blood test should prompt screening programmes to adopt effective interventions to increase compliance in this high-risk population.